A PET scan for detecting signs of Alzheimer's
Part of Brain & nervous system, Mental health clinical trials.
This trial uses a new type of PET scan to look for specific proteins in the brain that are linked to Alzheimer's disease. It will help doctors see how these proteins relate to cognitive decline and compare scans from people with normal thinking to those with memory problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be age 50 or older.
- You should have normal thinking, mild memory issues, or a diagnosis of Alzheimer's dementia.
- You need to be able to undergo a brain MRI and a PET scan.
- If you could become pregnant or get someone pregnant, you must use effective birth control during the study and for 3 months after.
- You cannot have other brain conditions like large strokes, certain dementias (like Lewy body or frontotemporal), or major mental illness.
- You cannot have taken certain experimental Alzheimer's treatments within the past 3 to 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special PET scan to look at a brain protein called PDE4 in people with Alzheimer's disease or mild cognitive impairment. It may help researchers understand how this protein is involved in memory and thinking problems.
This trial uses special PET scans to see amyloid and tau proteins in the brain, which are linked to Alzheimer's. It aims to find these changes early, in people with mild memory problems or early-stage Alzheimer's.
This study uses a special PET scan to take pictures of abnormal tau protein in the brain. It aims to see if the scan results match what is found in brain tissue after death, which could help improve diagnosis of Alzheimer's and related conditions.
This study uses special brain scans (PET scans) to look for proteins linked to Alzheimer's disease. It aims to improve diagnosis and track how the disease progresses over time.
This trial tests a new PET imaging agent (18F-XTR006) to see how well it shows brain changes related to Alzheimer's disease. It may help diagnose MCI (mild cognitive impairment) or Alzheimer's earlier by comparing images in healthy people and those with memory problems.
This study tests a PET scan “tracer” medicine called [18F]MK-6240 to see how tau protein changes show up in the brain. It may help researchers measure disease-related brain changes in people with normal thinking or mild dementia.
Hear when a new Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.